Diatrizoic acid
As of the edition of 20 October 2026, Diatrizoic acid is a small molecule: marketed, first approved in 1978 (CA).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1997
- Kind
- Small molecule
- Brand name
- Hypaque
- First approved
- 30 December 1978 (CA)
- Approvals on record
- 27 in 3 regions
- Holder of the most recent approval
- Bayer; 5 holders in all
- Registered trials
- 10, 2 stopped early
- Disease areas
- Digestive system; Bones, joints and muscles; Cancer; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 0 |
| Phase 2 | 1 | 0 | 0 | 0 |
| Phase 3 | 4 | 2 | 1 | 1 |
| Phase 4 | 3 | 2 | 0 | 1 |
| All trials | 10 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bracco Imaging | Applicant | 1978 to now |
| Bracco Diagnostics | Acquired holder | 2003 to now |
| Bristol Myers Squibb | Applicant | |
| GE Healthcare | Later holder |